Trade Kalaris Therapeutics INC - KLRS CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.31 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023679% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001457% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 7.67 |
| Open | 7.94 |
| 1-Year Change | 905.06% |
| Day's Range | 7.91 - 8.35 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 1, 2025 | 7.67 | -0.07 | -0.90% | 7.74 | 8.31 | 7.62 |
| Mar 31, 2025 | 7.94 | -0.55 | -6.48% | 8.49 | 8.62 | 7.67 |
| Mar 28, 2025 | 8.48 | -0.41 | -4.61% | 8.89 | 8.98 | 8.46 |
| Mar 18, 2025 | 9.68 | -0.11 | -1.12% | 9.79 | 10.19 | 9.48 |
| Mar 17, 2025 | 9.39 | -0.25 | -2.59% | 9.64 | 9.69 | 9.28 |
| Mar 14, 2025 | 9.63 | 0.29 | 3.10% | 9.34 | 9.65 | 9.28 |
| Mar 13, 2025 | 9.24 | -0.25 | -2.63% | 9.49 | 9.76 | 8.99 |
| Mar 12, 2025 | 9.35 | -0.06 | -0.64% | 9.41 | 9.49 | 9.03 |
| Mar 11, 2025 | 9.09 | -0.18 | -1.94% | 9.27 | 9.39 | 9.00 |
| Mar 10, 2025 | 9.19 | -0.32 | -3.36% | 9.51 | 9.68 | 9.19 |
| Mar 7, 2025 | 9.79 | -0.22 | -2.20% | 10.01 | 10.08 | 9.74 |
| Mar 6, 2025 | 9.69 | -0.09 | -0.92% | 9.78 | 9.86 | 9.55 |
| Mar 5, 2025 | 9.50 | -0.30 | -3.06% | 9.80 | 10.33 | 9.50 |
| Mar 4, 2025 | 9.59 | 0.15 | 1.59% | 9.44 | 9.67 | 9.19 |
| Mar 3, 2025 | 9.91 | 0.14 | 1.43% | 9.77 | 10.00 | 9.76 |
| Feb 28, 2025 | 9.76 | 0.26 | 2.74% | 9.50 | 10.15 | 9.39 |
| Feb 27, 2025 | 9.79 | -0.07 | -0.71% | 9.86 | 9.98 | 9.49 |
| Feb 26, 2025 | 9.71 | -0.43 | -4.24% | 10.14 | 10.14 | 9.67 |
| Feb 25, 2025 | 9.75 | -0.44 | -4.32% | 10.19 | 10.19 | 9.69 |
| Feb 24, 2025 | 10.19 | -0.06 | -0.59% | 10.25 | 10.71 | 10.01 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
AlloVir, Inc. Company profile
About Allovir Inc
AlloVir, Inc. is a late clinical-stage cell therapy company. The Company is engaged in developing allogeneic T-cell therapies to treat and prevent viral diseases. Its virus-specific T cell (VST) therapy platform enables to generate VSTs designed to restore immunity in patients with T cell deficiencies. Its product candidate includes Viralym-M (ALVR105), ALVR106, ALVR109, ALVR107 and ALVR108. Its lead product candidate, Viralym-M, is a multi- VST therapy targeting five viruses: BK virus (BKV), cytomegalovirus (CMV), adenovirus (AdV), Epstein-Barr virus (EBV), and human herpesvirus 6 (HHV-6). The ALVR106 is an allogeneic VST therapy developed to target diseases caused by four respiratory viruses: respiratory syncytial virus (RSV), influenza, parainfluenza virus (PIV), and human metapneumovirus (hMPV). Its LVR109 is an allogeneic VST therapy that targets severe acute respiratory syndrome coronavirus two (SARS-CoV-2).
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Allovir Inc revenues was not reported. Net loss increased from $69.8M to $172M. Higher net loss reflects Research and development increase from $46.1M to $100.1M (expense), Stock-based Compensation in SGA increase from $5.9M to $23.3M (expense), Stock-based Compensation in R&D increase from $3.6M to $20.6M (expense).
| Industry: | Bio Therapeutic Drugs |
1100 Winter Street
WALTHAM
MASSACHUSETTS 02451
US
News
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025
Coffee price forecast: 2025-2030 third-party coffee target
Coffee prices have cooled considerably in the past few months. Is a rebound in store or will they continue to fall?
09:42, 12 March 2025
The Simpsons predicted XRP to hit $589: Has the show got it right again?
Did the animated TV show predict a breakout for the XRP cryptocurrency?
11:00, 11 March 2025
Rolls-Royce share price forecast: third- party price target
Our Rolls-Royce share price forecast looks at the outlook for the FTSE 100-listed engineering company after a tough few years.
14:58, 10 March 2025
Gasoline petrol price forecast 2025-2030: Third-party price target
Discover third-party gasoline (petrol) price predictions for 2025 and beyond, with analyst targets, historical prices, and trading strategies.
10:27, 3 March 2025
USD forecast - third party data round up
The DXY hit a seven-month low in January, just a few months after a multi-decade peak in late September.
10:02, 27 February 2025
Microsoft Stock Price Forecast for 2025 and beyond: Third party price target
We assess the likely level of the Microsoft stock price in 5 years, and possible drivers behind the stock’s past performance. Read on...
18:29, 7 February 2025People also watch
Still looking for a broker you can trust?
Join the 710,000+ traders worldwide that chose to trade with Capital.com